The most notable companies in this group are Edwards Lifesciences Corp (NYSE:EW), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS).
The investment seeks capital appreciation.
The portfolio managers seeks to meet its investment objective by investing primarily in common stocks and other equity securities of companies that the portfolio managers believe have potential to bring substantial improvements in human health and healthcare systems. Under normal circumstances, the fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in equity securities of companies engaged in or supporting innovation in one or more healthcare or healthcare-related industries. The fund is non-diversified.
The average market capitalization across the Baillie Gifford Health Inn Eq K MF is 22.17B. The market cap for tickers in the group ranges from 6.29B to 43.5B. DXCM holds the highest valuation in this group at 43.5B. The lowest valued company is SWAV at 6.29B.
The average weekly volume growth across all stocks in the Baillie Gifford Health Inn Eq K MF was 37%. For the same stocks of the MF, the average monthly volume growth was -23% and the average quarterly volume growth was 48%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 72
P/E Growth Rating: 80
Price Growth Rating: 58
SMR Rating: 74
Profit Risk Rating: 66
Seasonality Score: 21 (-100 ... +100)